173 related articles for article (PubMed ID: 14715452)
1. Ontogenetic quinpirole treatments fail to prime for D2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats.
Brus R; Kostrzewa RM; Nowak P; Perry KW; Kostrzewa JP
Neurotox Res; 2003; 5(5):329-38. PubMed ID: 14715452
[TBL] [Abstract][Full Text] [Related]
2. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
Pollack AE; Yates TM
Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
[TBL] [Abstract][Full Text] [Related]
3. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
4. Ontogenetic SKF 38393 treatments sensitize dopamine D1 receptors in neonatal 6-OHDA-lesioned rats.
Gong L; Kostrzewa RM; Brus R; Fuller RW; Perry KW
Brain Res Dev Brain Res; 1993 Nov; 76(1):59-65. PubMed ID: 8306431
[TBL] [Abstract][Full Text] [Related]
5. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
6. Apomorphine priming alters the response of striatal outflow pathways to D2 agonist stimulation in 6-hydroxydopamine-lesioned rats.
Pollack AE; Turgeon SM; Fink JS
Neuroscience; 1997 Jul; 79(1):79-93. PubMed ID: 9178866
[TBL] [Abstract][Full Text] [Related]
7. Priming of a D1 dopamine receptor behavioural response is dissociated from striatal immediate-early gene activity.
Paul ML; Currie RW; Robertson HA
Neuroscience; 1995 May; 66(2):347-59. PubMed ID: 7477877
[TBL] [Abstract][Full Text] [Related]
8. Abnormal involuntary movement (AIM) expression following D2 dopamine agonist challenge is determined by the nature of prior dopamine receptor stimulation (priming) in 6-hydroxydopamine lesioned rats.
Drake JD; Kibuuka LN; Dimitrov KD; Pollack AE
Pharmacol Biochem Behav; 2013 Apr; 105():26-33. PubMed ID: 23369985
[TBL] [Abstract][Full Text] [Related]
9. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
Neal-Beliveau BS; Joyce JN
Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
[TBL] [Abstract][Full Text] [Related]
10. Neonatal 6-hydroxydopamine lesioning enhances quinpirole-induced vertical jumping in rats that were quinpirole primed during postnatal ontogeny.
Kostrzewa RM; Kostrzewa FP
Neurotox Res; 2012 Feb; 21(2):231-5. PubMed ID: 21853388
[TBL] [Abstract][Full Text] [Related]
11. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors.
Popoli P; Pèzzola A; Torvinen M; Reggio R; Pintor A; Scarchilli L; Fuxe K; Ferré S
Neuropsychopharmacology; 2001 Oct; 25(4):505-13. PubMed ID: 11557164
[TBL] [Abstract][Full Text] [Related]
12. Motor stimulant effects of caffeine in 6-hydroxydopamine-lesioned rats are dependent on previous stimulation of dopamine receptors: a different role of D1 and D2 receptors.
Fenu S; Morelli M
Eur J Neurosci; 1998 May; 10(5):1878-84. PubMed ID: 9751157
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
Engber TM; Marin C; Susel Z; Chase TN
Eur J Pharmacol; 1993 Jun; 236(3):385-93. PubMed ID: 8102970
[TBL] [Abstract][Full Text] [Related]
14. Subchronic intermittent caffeine administration to unilaterally 6-hydroxydopamine-lesioned rats sensitizes turning behaviour in response to dopamine D(1) but not D(2) receptor agonists.
Cauli O; Pinna A; Morelli M
Behav Pharmacol; 2005 Dec; 16(8):621-6. PubMed ID: 16286813
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D2 agonist priming in intact and dopamine-lesioned rats.
Kostrzewa RM; Kostrzewa JP; Nowak P; Kostrzewa RA; Brus R
Neurotox Res; 2004; 6(6):457-62. PubMed ID: 15639779
[TBL] [Abstract][Full Text] [Related]
16. D1 priming enhances both D1- and D2-mediated rotational behavior and striatal Fos expression in 6-hydroxydopamine lesioned rats.
Pollack AE; Thomas LI
Pharmacol Biochem Behav; 2010 Jan; 94(3):346-51. PubMed ID: 19800912
[TBL] [Abstract][Full Text] [Related]
17. Repeated stimulation of D1 dopamine receptors causes time-dependent alterations in the sensitivity of both D1 and D2 dopamine receptors within the rat striatum.
Hu XT; Brooderson RJ; White FJ
Neuroscience; 1992 Sep; 50(1):137-47. PubMed ID: 1357592
[TBL] [Abstract][Full Text] [Related]
18. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
19. Neonatal 6-hydroxydopamine and adult SKF 38393 treatments alter dopamine D1 receptor mRNA levels: absence of other neurochemical associations with the enhanced behavioral responses of lesioned rats.
Gong L; Kostrzewa RM; Li C
J Neurochem; 1994 Oct; 63(4):1282-90. PubMed ID: 7931280
[TBL] [Abstract][Full Text] [Related]
20. Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.
LaHoste GJ; Marshall JF
Behav Brain Res; 1990 May; 38(3):233-42. PubMed ID: 1973041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
